Literature DB >> 25067999

Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI.

Stefano Palmucci1.   

Abstract

Since its clinical introduction, several studies in literature have investigated gadolinium ethoxybenzhyl diethylenetriaminepentaacetic acid or gadoxetic acid (Gd-EOB-DTPA) properties. Following contrast injection, it provides dynamic vascular phases (arterial, portal and equilibrium phases) and hepatobiliary phase, the latter due to its uptake by functional hepatocytes. The main advantages of Gd-EOB-DTPA of focal liver lesion detection and characterization are discussed in this paper. Namely, we focus on the possibility of distinguishing focal nodular hyperplasia (FNH) from hepatic adenoma (HA), the identification of early hepatocellular carcinoma (HCC) and the pre-operative assessment of metastasis in liver parenchyma. Regarding the differentiation between FNH and HA, adenoma typically appears hypointense in hepatobiliary phase, whereas FNH is isointense or hyperintense to the surrounding hepatic parenchyma. As for the identification of early HCCs, many papers recently published in literature have emphasized the contribution of hepatobiliary phase in the characterization of nodules without a typical hallmark of HCC. Atypical nodules (no hypervascularizaton observed on arterial phase and/or no hypovascular appearance on portal phase) with low signal intensity in the hepatobiliary phase, have a high probability of malignancy. Finally, regarding the evaluation of focal hepatic metastases, magnetic resonance pre-operative assessment using gadoxetic acid allows for more accurate diagnosis.

Entities:  

Keywords:  Carcinoma; Gadolinium diethylenetriaminepentaacetic acid; Hepatocellular; Image enhancement; Liver; Magnetic resonance imaging

Year:  2014        PMID: 25067999      PMCID: PMC4110539          DOI: 10.4254/wjh.v6.i7.477

Source DB:  PubMed          Journal:  World J Hepatol


  60 in total

1.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

2.  Diffusion-weighted MRI in a liver protocol: its role in focal lesion detection.

Authors:  Stefano Palmucci; Letizia Antonella Mauro; Martina Messina; Brunella Russo; Giovanni Failla; Pietro Milone; Massimiliano Berretta; Giovanni Carlo Ettorre
Journal:  World J Radiol       Date:  2012-07-28

Review 3.  Hepatic metastases: basic principles and implications for radiologists.

Authors:  M E Baker; R Pelley
Journal:  Radiology       Date:  1995-11       Impact factor: 11.105

4.  Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.

Authors:  Tsutomu Tamada; Katsuyoshi Ito; Atsushi Higaki; Koji Yoshida; Akihiko Kanki; Tomohiro Sato; Hiroki Higashi; Teruki Sone
Journal:  Eur J Radiol       Date:  2011-02-18       Impact factor: 3.528

5.  Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging.

Authors:  Chen-Te Chou; Jung-Mao Chou; Ting-An Chang; Shiu-Feng Huang; Chia-Bang Chen; Yao-Li Chen; Ran-Chou Chen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

6.  Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

Authors:  Taku Tajima; Hidemasa Takao; Hiroyuki Akai; Shigeru Kiryu; Hiroshi Imamura; Yasushi Watanabe; Jyunichi Shibahara; Norihiro Kokudo; Masaaki Akahane; Kuni Ohtomo
Journal:  J Comput Assist Tomogr       Date:  2010 May-Jun       Impact factor: 1.826

7.  MR findings of steatotic focal nodular hyperplasia and comparison with other fatty tumours.

Authors:  Maxime Ronot; Valérie Paradis; Rafael Duran; Anne Kerbaol; Marie-Pierre Vullierme; Jacques Belghiti; Dominique-Charles Valla; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2012-10-14       Impact factor: 5.315

8.  Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA.

Authors:  Hun-Kyu Ryeom; Seong-Hun Kim; Jong-Yeol Kim; Hye-Jeong Kim; Jong-Min Lee; Yong-Min Chang; Yong-Sun Kim; Duk-Sik Kang
Journal:  Korean J Radiol       Date:  2004 Oct-Dec       Impact factor: 3.500

9.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 10.  The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase.

Authors:  Woo Kyoung Jeong; Young Kon Kim; Kyoung Doo Song; Dongil Choi; Hyo Keun Lim
Journal:  Clin Mol Hepatol       Date:  2013-12-28
View more
  18 in total

Review 1.  Gd-EOB-DTPA-Enhanced Magnetic Resonance Findings of a Giant Inflammatory Hepatocellular Adenoma: a Case Report and Review of the Literature.

Authors:  Marco Di Pietropaolo; Chiara Briani; Emanuela Pilozzi; Francesco Carbonetti; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2015-12

Review 2.  Benign solid tumors of the liver: management in the modern era.

Authors:  Georgios Antonios Margonis; Aslam Ejaz; Gaya Spolverato; Neda Rastegar; Robert Anders; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

Review 3.  Gd-EOB-DTP-enhanced MRC in the preoperative percutaneous management of intra and extrahepatic biliary leakages: does it matter?

Authors:  Mario Petrillo; Anna Maria Ierardi; Laura Tofanelli; Duilia Maresca; Alessio Angileri; Francesca Patella; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2019-04

4.  Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-03-14       Impact factor: 5.315

5.  Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

Authors:  Jielin Pan; Wenjuan Li; Lingjing Gu; Chaoran Liu; Ke Zhang; Guobin Hong
Journal:  Eur Radiol       Date:  2022-05-17       Impact factor: 5.315

6.  Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations.

Authors:  Hiroki Haradome; Toshiyuki Unno; Hiroyuki Morisaka; Yusuke Toda; Thomas C Kwee; Hiroshi Kondo; Keiji Sano; Tomoaki Ichikawa; Fukuo Kondo; Masahiko Sugitani; Tadatoshi Takayama
Journal:  Eur Radiol       Date:  2017-04-24       Impact factor: 5.315

7.  Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities.

Authors:  Christian Sturesson; Jan Nilsson; Gert Lindell; Roland G Andersson; Inger Keussen
Journal:  HPB (Oxford)       Date:  2015-08-07       Impact factor: 3.647

Review 8.  Latest developments in precancerous lesions of hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang; Jing Zhao
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

9.  Concurrent hepatic hemangioma and solitary fibrous tumor: diagnosis and management.

Authors:  Michael Kueht; Prakash Masand; Abbas Rana; Ronald Cotton; John Goss
Journal:  J Surg Case Rep       Date:  2015-07-24

10.  Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Xiang Li; Chenxia Li; Rong Wang; Juan Ren; Jian Yang; Yuelang Zhang
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.